Aceclidine

Aceclidine
Clinical data
Other names	LNZ101
AHFS/Drugs.com	Vizz
License data	US DailyMed: Aceclidine;
Routes of; administration	Topical (ophthalmic solution)
ATC code	S01EB08 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-Azabicyclo[2.2.2]oct-3-yl acetate; 3-Quinuclidinyl Acetate;
CAS Number	827-61-2 ; 6109-70-2;
PubChem CID	1979;
ChemSpider	1902;
UNII	0578K3ELIO;
KEGG	D02750;
ChEMBL	ChEMBL20835;
CompTox Dashboard (EPA)	DTXSID2045658 ;
ECHA InfoCard	100.011.431
Chemical and physical data
Formula	C9H15NO2
Molar mass	169.224 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OC2C1CCN(CC1)C2)C;
	InChI InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3; Key:WRJPSSPFHGNBMG-UHFFFAOYSA-N;

Aceclidine (Glaucostat, Glaunorm, Glaudin, Vizz) is a parasympathomimetic miotic agent used in the treatment of narrow angle glaucoma.

Aceclidine was approved for medical use in the United States in July 2025.^[2]

Medicinal properties

Aceclidine decreases intraocular pressure. It acts as a muscarinic acetylcholine receptor agonist.^[3]

Chemistry

Aceclidine is an organic compound that is structurally related to quinuclidine. As such its alternative name is 3-acetoxyquinuclidine. Its protonated derivative has a pKa of 9.3.^[4]

References

^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218585s000lbl.pdf
^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 4 August 2025. Retrieved 5 August 2025.
^ Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, et al. (August 1999). "Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats". The Journal of Pharmacology and Experimental Therapeutics. 290 (2): 901–907. doi:10.1016/S0022-3565(24)34979-1. PMID 10411607.
^ Aggarwal VK, Emme I, Fulford SY (February 2003). "Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope". The Journal of Organic Chemistry. 68 (3): 692–700. doi:10.1021/jo026671s. PMID 12558387.

External links

Clinical trial number (NCT05656027 for "Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov
Clinical trial number (NCT05728944 for "Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (CLARITY)" at ClinicalTrials.gov
Clinical trial number (NCT05753189 for "Phase 3 Safety Study for the Treatment of Presbyopia Subjects" at ClinicalTrials.gov

[Vizz_FDA_label-1] ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218585s000lbl.pdf

[2] "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 4 August 2025. Retrieved 5 August 2025.

[pmid10411607-3] Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, et al. (August 1999). "Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats". The Journal of Pharmacology and Experimental Therapeutics. 290 (2): 901–907. doi:10.1016/S0022-3565(24)34979-1. PMID 10411607.

[4] Aggarwal VK, Emme I, Fulford SY (February 2003). "Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope". The Journal of Organic Chemistry. 68 (3): 692–700. doi:10.1021/jo026671s. PMID 12558387.

[1]

[2]

[3]

[4]